#新冠药物
西湖大学抗新冠病毒口服药获批进入临床试验
从西湖大学获悉，经过两年多的努力，该校生命科学学院院长、西湖实验室主任于洪涛领衔攻关研发的抗新冠病毒口服药WPV01(艾普司韦)经国家药审中心批准，日前正式进入临床试验阶段。我国对该药物拥有完全自主知识产权。（浙江新闻）
BY 选股宝 快讯
That growth environment will include rising inflation and interest rates. Those upward shifts naturally accompany healthy growth periods as the demand for resources, products and services rise. Importantly, the Federal Reserve has laid out the rationale for not interfering with that natural growth transition.It's not exactly a fad, but there is a widespread willingness to pay up for a growth story. Classic fundamental analysis takes a back seat. Even negative earnings are ignored. In fact, positive earnings seem to be a limiting measure, producing the question, "Is that all you've got?" The preference is a vision of untold riches when the exciting story plays out as expected.
A project of our size needs at least a few hundred million dollars per year to keep going,” Mr. Durov wrote in his public channel on Telegram late last year. “While doing that, we will remain independent and stay true to our values, redefining how a tech company should operate.
选股宝 快讯 from us